Insider Selling: Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CEO Sells $1,252,511.88 in Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CEO Jeremy Bender sold 70,051 shares of the company’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $17.88, for a total transaction of $1,252,511.88. Following the completion of the transaction, the chief executive officer now directly owns 651,762 shares of the company’s stock, valued at $11,653,504.56. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Jeremy Bender also recently made the following trade(s):

• On Friday, May 3rd, Jeremy Bender sold 9,154 shares of Day One Biopharmaceuticals stock. The stock was sold at an average price of $17.85, for a total transaction of $163,398.90.
• On Friday, February 16th, Jeremy Bender sold 7,615 shares of Day One Biopharmaceuticals stock. The stock was sold at an average price of $15.25, for a total transaction of $116,128.75.

Day One Biopharmaceuticals Stock Performance

Shares of DAWN stock opened at $17.17 on Monday. The firm’s 50-day moving average is $15.45 and its 200-day moving average is $14.07. The stock has a market cap of $1.50 billion, a price-to-earnings ratio of -7.21 and a beta of -1.44. Day One Biopharmaceuticals, Inc. has a 52-week low of $9.67 and a 52-week high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its earnings results on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). Sell-side analysts predict that Day One Biopharmaceuticals, Inc. will post -2.67 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

DAWN has been the subject of a number of recent research reports. Piper Sandler restated an “overweight” rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research note on Tuesday, March 26th. JPMorgan Chase & Co. increased their price objective on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an “overweight” rating in a research note on Monday, April 22nd. Wedbush restated an “outperform” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research note on Wednesday, April 24th. The Goldman Sachs Group reduced their price objective on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating for the company in a research note on Tuesday, February 27th. Finally, Oppenheimer restated a “market perform” rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Day One Biopharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $39.33.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. raised its holdings in Day One Biopharmaceuticals by 67.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 16,817 shares of the company’s stock valued at $278,000 after acquiring an additional 6,750 shares during the period. Hennion & Walsh Asset Management Inc. raised its holdings in Day One Biopharmaceuticals by 2.5% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 59,289 shares of the company’s stock valued at $979,000 after acquiring an additional 1,445 shares during the period. Fisher Asset Management LLC raised its holdings in Day One Biopharmaceuticals by 89.0% in the 4th quarter. Fisher Asset Management LLC now owns 68,446 shares of the company’s stock valued at $999,000 after acquiring an additional 32,238 shares during the period. Wellington Management Group LLP raised its holdings in Day One Biopharmaceuticals by 77.7% in the 4th quarter. Wellington Management Group LLP now owns 208,969 shares of the company’s stock valued at $3,051,000 after acquiring an additional 91,393 shares during the period. Finally, Goldman Sachs Group Inc. raised its holdings in Day One Biopharmaceuticals by 28.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock valued at $30,935,000 after acquiring an additional 472,654 shares during the period. 87.95% of the stock is owned by institutional investors.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.